Skip to main content

Table 1 Scores prior to autologous hematopoietic stem cell transplantation

From: Low toxicity and favorable clinical and quality of life impact after non-myeloablative autologous hematopoietic stem cell transplant in Crohn’s disease

Patient#

HBI

CSI

Montreal

CDEIS

SES-CD

Rutgeerts

CDAI

1

37

30

A2 L4 B2

17

18

i4

450.5

2

18

22

A3 L3 B2

6

8

247

3

22

20

A1 L3 B1

11

14

306

4

48

35

A1 L1 B1

427

5

15

28

A2 L3 B2

1

4

240

6

14

23

A2 L3 B1

7

6

i4

250

7

15

32

A2 L3 B1p

15

22

261

8

14

20

A2 L3 B2

14

14

i4

273.7

9

21

31

A3 L3 B3p

308

10

22

28

A3 L3 B3p

8

7

i4

260

11

16

16

A2 L3 B2

10

13

i4

284.8

12

13

36

A2 L3 B2P

36

24

i4

287.5

13

14

34

A2 L3 B2

34

11

i4

186

14

11

17

A1 L3 B2P

155

Mean ± SD

20 ± 10.3

26.5 ± 6.8

 

14.5 ± 11.1

12.8 ± 6.5

 

281.2

  1. HBI Harvey–Bradshaw index; CSI Crohn’s severity index; CDEIS Crohn’s disease endoscopic index of severity; SES-CD simple endoscopic score for Crohn’s disease; CDAI Crohn’s disease activity index; SD standard deviation